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Supplementary Figures
Fig. S1
Compound 3 docked pose in the co-crystal structure of CD38 and cIDPR a) southern ribose pulled out of plane b) overlap of triazole and pyrophosphate groups. Modelling-Compounds 3 and 4 were built and minimised using the Schrödinger software. The 2PGJ structure was passed through the Protein Preparation Wizard of the Schrödinger software after the structure of the ligand in the crystal structure was corrected. Ligands were docked using GOLD with the binding site defined as a sphere of 5Å radius centred on the centroid of the ligand in the binding site. Each ligand was docked 25 times.
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NaHCO 3 (sat. aq.), then brine, dried (Na 2 SO 4 ) and evaporated to dryness. The residue was purified by column chromatography on silica gel eluting with PE:EtOAc (1:0 → 1:0 v/v) 1, 169.6, 169.5, 154.4, 147.7, 144.4, 126.2, 124.9, 115.1, 90.8, 87.6, 85.5, 83.5, 81.6, 80.4, 74.2, 70.2, 63.0, 51.8, 27.2, 25.3, 20.7, 20.4, 20.3 7, 148.4, 145.9, 126.5, 124.5, 115.0, 92.2, 91.0, 85.8 (2C), 83.4, 81.7, 75.3, 70.1, 61.5, 51.9, 27.1, 25 
N1-(2,3-O-isopropylidene--D-ribofuranosyl)-5-azido-5-deoxy-2,3-O-isopropylidene-8-
bromoinosine 11 -To 10 (75 mg, 0.14 mmol) in acetone-2,2-dimethoxypropane (2.5 mL, 4:1 v/v) was added p-TsOH (26 mg, 0.14 mmol). After 1 h, DCM and NaHCO 3 (sat. aq.) were added, and the organic layer dried (Na 2 SO 4 ) and evaporated to dryness. 146.6, 126.5, 125.6, 115.1, 114.3, 96.6, 90.9, 87.9, 85.6, 83.6, 83.5, 81.7, 80.6, 62.7, 51.9, 27.3, 27.1, 25. 7, 148.1, 145.8, 126.1, 125.3, 115.0, 114.2, 94.2, 90.9, 87.1, 85.8, 85.7, 83.7, 81.9, 81.4, 78.8, 75.4, 69.9, 58.6, 52.0, 27.22, 27.20, 25.4, 25.3 CH), 6.09 (d, 1H, J = 1.2, H-1′), 5.84 (d, 1H, J = 1.5, H-1′′), 5.21 (t, 1H, J = 6.6, H-3′), 5.04 (dd, 1H, J = 6.6, 1.2, H-2′), 4.94 (dd, 1H, J = 15.1, 1.4, H-5′a), 4.89 (dd, 1H, J = 5.6, 1.5, H-2′′), 4. 5, 127.4, 125.1, 94.6, 93.5, 85.7, 82.3, 76.9, 74.1, 69.64, 69.58, 69.3, 65. 8, 147.7, 144.5, 143.7, 142.0, 126.7, 123.4, 92.4, 91.1, 84.1, 79.6, 75.4, 73.4, 68.4, 68.1, 67.7, 63.9, 48.5 
N1-(2,3-O-isopropylidene-5-O-propargyl--D-ribofuranosyl)-5-azido-5-deoxy-2,3-O-
N1-Cyclic-2,3-O-isopropylidene-8-bromoinosine-5-deoxy-5-(4-methyl-1,2,3-triazole)-2,3-O-
N1-Cyclic
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(11 mg, 0.17 mmol) was added and the resulting suspension stirred at 70 C in the dark for 16 h, after which a second portion of NaN 3 (11 mg, 0.17 mmol) was added and the suspension stirred for a further 16 h, after which full conversion of the starting material to product was observed by HPLC ( = 255 nm   = 277 nm). All solvent was evaporated and the resulting residue co-evaporated with MilliQ (2 × 5 mL). The residue was then taken up in MilliQ (5 mL), filtered through cotton wool, and purified by semi-preparative 3, 148.2, 145.0, 143.8, 143.7, 126.3, 121.9, 92.7, 89.5, 84.1, 81.5, 75.7, 73.1, 68.7, 68.1, 68.0, 65.5, 49.3 147.5, 143.7, 141.8 (2C), 126.7, 120.1, 92.5, 88.8, 84.2, 79.5, 75.6, 72.9, 68.4, 67.9, 67.8, 64.0, 48.7 Enzymatic Assay for cADPR Hydrolysis-The inhibition of cADPR hydrolysis by various concentrations of analogue (0-1 mM) was determined by incubating 1 M cADPR with 1 g/ml of CD38 for 10 min at 20 -
N1-Cyclic
